Navigation Links
Experimental drug prolongs life span in mice

CHICAGO --- Northwestern Medicine scientists have newly identified a protein's key role in cell and physiological aging and have developed in collaboration with Tohoku University in Japan -- an experimental drug that inhibits the protein's effect and prolonged the lifespan in a mouse model of accelerated aging.

The rapidly aging mice fed the experimental drug lived more than four times longer than a control group, and their lungs and vascular system were protected from accelerated aging, the new study reports.

The experimental drug could potentially be used to treat human diseases that cause accelerated aging such as chronic kidney disease, diabetes and HIV infection as well as the effects of cigarette smoking.

"A drug like this could help reduce complications in clinical conditions that reflect accelerated aging," said Douglas Vaughan, M.D., senior author of the study. "This had a very robust effect in terms of prolonging life span."

Vaughan is the chair of medicine and the Irving S. Cutter Professor at Northwestern University Feinberg School of Medicine and physician-in-chief at Northwestern Memorial Hospital.

This is a completely different target and different drug than anything else being investigated for potential effects in prolonging life, Vaughan noted.

While the experimental drug is in the early stages of testing, Vaughan said, "It makes sense that this might be one component of a cocktail of drugs or supplements that a person might take in the future to extend their healthy life."

The study was published April 28 in Proceedings of the National Academy of Sciences.

The experimental drug, TM5441, is one of only several chosen each year by the National Institute on Aging to be tested in its Interventions Testing Program, which investigates treatments with the potential to extend lifespan and delay disease in mice.

The discovery is the result of 25 years of research by Vaughan's lab.

When cells or tissue age -- called senescence -- they lose the ability to regenerate and secrete certain proteins, like a distinctive fingerprint. One of those proteins, PAI-1 (plasminogen activator inhibitor) has been the focus of Vaughan's research, originally as it relates to cardiovascular disease.

"We made the intellectual leap between a marker of senescence and physiological aging," Vaughan said. "We asked is this marker for cell aging one of the drivers or mechanisms of rapid physiological aging?"

For the study, he and colleagues used mice bred to be deficient in a gene (Klotho) that suppresses aging. These mice exhibit accelerated aging in the form of arteriosclerosis, neurodegeneration, osteoporosis and emphysema and have much shorter life spans than regular mice. Vaughan determined that these rapidly aging mice produce increased levels of PAI-1 in their blood and tissue.

Then scientists fed the rapidly aging mice TM5441 -- the experimental drug -- in their food every day. The result was a decrease in PAI-1 activity (the aging protein Vaughan's team had identified), which quadrupled the mice's life span and kept their organs healthy and functioning.

Northwestern scientists also genetically produced the same life prolonging results when they crossed the mice deficient in the age-suppressing gene with mice deficient in PAI-1. Importantly, partial genetic deficiency of PAI-1 and the experimental PAI-1 antagonist produced provided similar benefits in the mice, Vaughan noted.


Contact: Marla Paul
Northwestern University

Related medicine news :

1. Experimental drug shows promise for treatment-resistant leukemias
2. Diabetes drug shows promise in reducing Alzheimers disease in an experimental model
3. Experimental drug could enhance multiple myeloma and myeloid leukemia therapies
4. Experimental drug shows encouraging results in treating most common form of lung cancer
5. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
6. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
7. York physicists offer novel insight into experimental cancer treatment
8. Experimental Drug Shows Benefits Against Melanoma in Early Study
9. Experimental Drugs Show Promise Against Prostate Cancer
10. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
11. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men ... prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown ... helped advance the healthcare industry as a whole through their advocacy and professional ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... -- Research and Markets ( ) has announced ... 2015-2019" report to their offering. ... the author the present scenario and growth prospects of ... the market size, the report considers revenue generated from ... and copper IUDs. The report forecasts the global intrauterine ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
Breaking Medicine Technology: